Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(AstraZeneca) D419CC00002 / HIMALAYAA Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma Zbuk, Dr KevinOpenNCT03298451
(MacroGenics) CP-MGAH22-05A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric CancerJuergens, Dr RosalynOpenNCT02689284
(Merck) MK-3475-590 / KEYNOTE 590A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)Juergens, Dr RosalynOpenNCT03189719
(PMH) OZM-067 / LuNETA Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment with individualized dosimetry in Patients with 68Ga-DOTATATE identified Somatostatin Receptor Positive Neuroendocrine TumorsJuergens, Dr RosalynOpenNCT02743741
RTOG 1112Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular CarcinomaSwaminath, Dr AnandOpenNCT01730937
(CCTG) CO.21 / CHALLENGEA Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE)Goffin, Dr JohnOn holdNCT00819208
Download PDF